PO-02 - Retrospective audit of the Peripherally Inserted Central Catheter (PICC) associated thrombosis in patients with haematological malignancies at Cork University Hospital

McAuliffe, Ellen; O’Shea, Susan; Khan, Muhammad Irfan

doi:10.1016/s0049-3848(16)30135-9

Cited by 6 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patients, the incidence of CRT was 9%. In other experiences in high-risk hematologic patients, the reported CRT incidence was similar to our data, between 7.8 and 11.7%, [16][17][18][19]. The high incidence observed could be associated to allo-HSCT procedures and complications: acute graft-vs-host disease and high dosages of steroids treatment [20].…”

Section: Discussionsupporting

confidence: 90%

“…In our experience, we did not observe difference in CRT incidence related to the lumen size, 4 vs 5 French. In a recent retrospective study in hematologic patients, PICC lumen size influenced the risk of thrombotic complication, with 20 and 13% of thrombosis observed with 6 and 5 French catheters, respectively [16]. In our study, CRT did not represent a severe complication in allo-HSCT and the occurrence of CRT never required an early PICC removal.…”

Section: Discussionsupporting

confidence: 52%

See 1 more Smart Citation

Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients

Mariggiò

Iori

Micozzi

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

Background Central venous catheters (CVC) are essential for the management of patients with hematologic malignancies, facilitating chemotherapy infusion, antibiotics, parenteral nutrition, blood products, and blood samples collection. In this population, peripherally inserted central catheters (PICC) seem to be associated with lower complications, compared with conventional percutaneously inserted devices (CICC). Data on the PICC in allogeneic hematopoietic stem cell recipients (allo-HSCT) are limited. Methods We have prospectively evaluated the safety and efficacy of 100 polyurethanes or silicone PICC, inserted into 100 adult allo-HSCT recipients, at the Hematology of Sapienza University of Rome (Italy), between October 2012 and August 2017. ResultsThe median duration of PICC placement was 117 days. Overall, 68% of patients maintained the device for the entire transplant procedure and PICC were removed after day 100 from allo-HSCT; of these, 44% did not experienced any PICC-related complications. Catheter-related bloodstream infections (CRBSI) occurred in 32% of patients (2.5/1000 PICC days), associated with thrombosis in 8 cases. CRBSI were observed in 42% of patients with polyurethane and 20% with silicone PICC (p = 0.02). Catheter-related thrombosis occurred in 9% of patients, never requiring anticipated PICC removal. Mechanical complications occurred in 15% of cases (1.2/1000 PICC days). On the whole, adverse events were manageable and did not affect transplant outcome. No deaths related to PICC-complications were observed. Conclusions PICC are a safe and reliable long-term venous access in allo-HSCT recipients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 52%

Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients

Mariggiò

Iori

Micozzi

et al. 2020

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Study design varied with the most common type using a retrospective design. We included nine retrospective study designs, [15][16][17][18][19][20][21][22][23] four guidelines, [24][25][26][27] two prospective design studies, 14,28 two literature reviews, 11,29 one survey, 30 one case study 31 and one cross sectional analysis. 32 Among the reports included, no randomised control trials (RCTs), no systematic reviews, no meta-analysis or meta-synthesis and no scoping reviews were identified.…”

Section: Characteristics Of Sources Of Evidencementioning

confidence: 99%

“…To also monitor rates of peripheral intravenous cannula adverse events and blood culture contamination rates before and after the changeover of doctors Practitioners (HCPs), 14,21,25,26,27 20% (n = 4) reported on complications associated with VADs, 11,22,29,32 10% (n = 2) reported on complications of a peripherally inserted central catheter (PICC) in haematology patients, 16,19 10% (n = 2) reported on education for parents of paediatric patients 18,30 and 5% (n = 1) reported on VAD choice by the patient. 31 Our review on sample sizes found that two sample sizes were not specified, 28,30 six sample sizes were not applicable, 11,[24][25][26][27]29 four sample sizes had under 50 patients, 14,17,21,31 three had sample sizes between 50 and 100 patients, 15,19,23 one was between 100 and 500 patients, 16 two were between 500 and 1000 patients 18,20 and two were over 1000 patients. 22,32 We found no evidence of study protocol publication and no study was registered as a clinical trial.…”

Section: Funding Not Mentionedmentioning

confidence: 99%

See 1 more Smart Citation

A scoping review of Clinical Studies, Hospital Group Reports and National Strategic Documents on vascular access devices in cancer patients

2021

View full text Add to dashboard Cite

Introduction: The extent of vascular/venous access device (VAD) research output from the Island of Ireland is unknown. The identification of the papers available is important to create a future research agenda. Objectives: The main objective of this study is to answer three questions: What is the number and descriptive quality of reported Vascular Access Device literature from the Island of Ireland? Is the reporting of Catheter Related Infection rates for cancer patients common in Irish Hospital Groups, National Cancer Reports and Publication Outputs? What are the implications for future research in this area? Methods: We used a scoping review and searched selected databases, grey literature and hospital regulatory bodies websites following the Joanna Briggs Institute Guidelines 2017. A data charting form was developed based on a template from the Joanna Briggs Institute and this was used to extract data from the included reports. Results: A total of 660 reports were screened. Sixty-one full text articles were reviewed from which 20 reports were included for data extraction. Of the reports included the following designs were used: nine retrospective study designs, four guidelines, two prospective study designs, two literature reviews and one of the following; survey, case study and cross sectional analysis designs. We did not identify any randomised controlled trials, systematic reviews, meta-analysis, meta-synthesis and scoping reviews. Five studies included catheter related infection rates. Gaps in the research include the collection of data sets and the need to establish a VAD registry; develop core outcomes for VADs; assessment and evaluation of VAD care bundles among cancer patients; and, the inclusion of public and patient involvement in future VAD research. Conclusion: The reporting of VAD outcomes in published literature regarding cancer patients receiving treatment in Ireland is inconsistent and varied with no interventional studies addressing vascular access complications in cancer care.

show abstract

PICC-Line-Anlage

2020

View full text Add to dashboard Cite

PO-02 - Retrospective audit of the Peripherally Inserted Central Catheter (PICC) associated thrombosis in patients with haematological malignancies at Cork University Hospital

Cited by 6 publications

References 0 publications

Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients

Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients

A scoping review of Clinical Studies, Hospital Group Reports and National Strategic Documents on vascular access devices in cancer patients

PICC-Line-Anlage

Contact Info

Product

Resources

About